Previous Close | 2.3000 |
Open | 2.3300 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 2.2900 - 2.3850 |
52 Week Range | 1.8600 - 6.9490 |
Volume | |
Avg. Volume | 3,515 |
Market Cap | 16.978M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for ALPHE.PA
NANTES, France, January 25, 2023--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy for the treatment of resistant and/or complicated bacterial infections, announced today that its management team will participate in the following scientific and investor events:
NANTES, France, January 03, 2023--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announced its financial agenda for 2023.
NANTES, France, December 15, 2022--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE, eligible for PEA-PME equity savings plans) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that the Combined General Meeting of December 15, 2022 was able to deliberate, the quorum having been reached.